Portfolio Summary:
- Total Value (including cash): 100% of sleeve
- Total Gain/Loss: +2.0%
- Cash Available: ~60% of sleeve
- Realized Loss (from WGS sale): -0.09% of sleeve
Note: The portfolio is watching SLDP and RNA for potential new entries. COST (Costco) remains on the watchlist as a potential quality anchor.
Current Holdings
| Ticker | Company Name | Sector | Buy Date | Allocation (%) | Cost Basis | Current Price | Gain/Loss (%) | Notes |
|---|---|---|---|---|---|---|---|---|
| CRNX | Crinetics | Biotech | 6/13/25 | ~25% | $31.84 | $30.99 | -2.7% | |
| VKTX | Viking | Biotech | 7/2/25 | ~12% | $27.73 | $34.42 | +24.1% | |
| VNET | VNET Group | Data | 7/10/25 | ~2% | $7.00 | $8.26 | +18.0% | |
| SLDP | Solid Power | Battery | — | 0% | $2.20 | $4.31 | 0.0% | Target position (inactive) |
| RNA | Avidity Bio | Biotech | — | 0% | $28.00 | $36.27 | 0.0% | Target position (inactive) |
| Cash | — | — | — | ~60% | n/a | n/a | n/a | High reserve for flexibility |
Realized Gains/Losses
| Ticker | Company Name | Sector | Buy Date | Sold Date | Allocation (%) | Gain/Loss (%) | Notes |
|---|---|---|---|---|---|---|---|
| WGS | GeneDx Holdings | Genomics | 7/16/25 | 7/22/25 | small (<1%) | -2.2% | Sold due to lawsuit risk |
Market Context & Relative Performance
- S&P 500 up 1.5% this week
- Russell 2000 Growth up 0.9% this week
-
Moonshot Portfolio up 0.6% this week, despite maintaining over 60% in cash.
This sizable cash cushion shows a defensive, flexible approach—ready to capitalize on future opportunities as volatility and valuation dislocations unfold.
Update Summary
- WGS Position: Exited immediately upon lawsuit headlines, reducing exposure to potential legal and headline-driven volatility.
- Risk Management: Adaptive discipline and high cash reserve shielded the portfolio from larger losses.
- Cash Buffer: With cash levels above 60%, strategy is prepared for opportunistic buys in coming weeks.
Bottom Line
Decisive action in selling WGS in response to legal risk reinforces the portfolio’s proactive risk management. Keeping a high cash reserve preserved flexibility and reduced volatility, while conviction core holdings contributed upside.
As market conditions shift, this defensive yet tactical approach is set to capitalize on the next real moonshot opportunities, rather than being forced to ride out volatility fully invested and exposed.